

## PRESS RELEASE

### PersonalMed Study Finds Excluding Compounds Increased Total Cost of Care for a Large Union Group

The Compounding Program Analysis Finds Blind Spots in Current Compound Management Strategies.

Houston, TX – June 23, 2015 – PersonalMed LLC, a leader in the management of compound medications for payers, today announced the release of a new white paper, “[The True Costs of Excluding Compounds](#).” This publication is the result of a study conducted by an independent consultant using medical and pharmacy claims information from multiple plan sponsor clients with a 2 year enrollment of over 18 million member months.

The report presented findings derived from the comparison of two very similar plans using clinical analysis, advanced analytics, research expertise and proprietary technology. The research showed that a complete exclusion of compound medications for the treatment of pain led to a 10% increase in pain-related medical expenditure, an average of \$500 per treated pain patient per month.

“We believe that compounding pharmacists and compound medications provide unique clinical value to patients to who would otherwise face very limited and inefficient clinical choices,” said Del Doherty, Pharm.D., Ph.D., MPH, Vice President of Managed Care. This study is an example of how well-designed, data-driven evaluations of a plan sponsor’s medical and pharmacy claims information can be utilized to identify unique opportunities of how compound medications can enhance plan sponsors’ benefits and provide tangible savings on the medical spend.”

Results from the “The Opportunity Costs of Excluding Compounds” was recently featured in a [webinar, Rethinking Compounds: Effective Compounding Management Strategies](#), hosted by the [Pharmacy Benefits Management Institute](#) (PBMI), following the launch of PersonalMed’s [Compound Program Management](#), a comprehensive management solution that focuses on Evidenced-Based Compounding (EBC), Billing Compliance through a proprietary compounding claims management platform, Pago, and an ongoing Compounding Program Analysis (CPA), a proprietary analytical tool.

### About PersonalMed

PersonalMed is a network of highly credentialed pharmacies with nationwide access for patients to receive quality care with personalized medication when clinically appropriate. With over 34 years’ experience in the compounding space, PersonalMed’s clinical resource team takes over 120,000 clinical consulting calls a year and has unique visibility into new therapeutic approaches and an unparalleled institutional knowledge of compounding.

**For Inquiries:**

Aaron Lopez, JD

Snr. Director of Public Affairs

PCCA